Avantax Advisory Services Inc. Buys Shares of 5,448 CRISPR Therapeutics AG (NASDAQ:CRSP)

Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,448 shares of the company’s stock, valued at approximately $341,000.

Several other large investors have also recently bought and sold shares of the stock. Teacher Retirement System of Texas increased its stake in CRISPR Therapeutics by 5.0% during the third quarter. Teacher Retirement System of Texas now owns 21,284 shares of the company’s stock valued at $966,000 after acquiring an additional 1,015 shares during the period. California Public Employees Retirement System lifted its holdings in shares of CRISPR Therapeutics by 5.9% during the 3rd quarter. California Public Employees Retirement System now owns 112,169 shares of the company’s stock worth $5,091,000 after acquiring an additional 6,207 shares during the period. Private Advisor Group LLC raised its position in CRISPR Therapeutics by 12.3% in the third quarter. Private Advisor Group LLC now owns 5,654 shares of the company’s stock worth $254,000 after purchasing an additional 618 shares in the last quarter. SteelPeak Wealth LLC grew its stake in shares of CRISPR Therapeutics by 14.6% in the 3rd quarter. SteelPeak Wealth LLC now owns 5,780 shares of the company’s stock valued at $262,000 after purchasing an additional 735 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in shares of CRISPR Therapeutics by 137.9% during the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,035 shares of the company’s stock worth $48,000 after buying an additional 600 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRSP has been the topic of several recent analyst reports. Royal Bank of Canada boosted their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research note on Thursday, February 22nd. Morgan Stanley upped their price objective on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research note on Monday, February 26th. Mizuho boosted their target price on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Wolfe Research began coverage on CRISPR Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Oppenheimer decreased their target price on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $73.57.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 9,802 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $78.26, for a total value of $767,104.52. Following the sale, the chief executive officer now directly owns 203,705 shares in the company, valued at $15,941,953.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Samarth Kulkarni sold 9,802 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $78.26, for a total transaction of $767,104.52. Following the sale, the chief executive officer now owns 203,705 shares of the company’s stock, valued at $15,941,953.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Raju Prasad sold 3,524 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total value of $256,159.56. Following the completion of the transaction, the chief financial officer now owns 6,476 shares of the company’s stock, valued at $470,740.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,709 shares of company stock worth $3,865,228. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Down 1.9 %

CRSP stock opened at $55.73 on Friday. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The business’s fifty day moving average is $60.59 and its 200-day moving average is $65.51. The company has a market cap of $4.73 billion, a P/E ratio of -20.49 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $25.53 million. The company’s revenue was down 99.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.67) EPS. Research analysts anticipate that CRISPR Therapeutics AG will post -5.64 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.